in more than one form (2, 3) . Seven of the known private specificities (H-2. 15, 17, 19, 20, 23, 3l, 33 ) can be assigned definitely to H-2K, five (H-2. 2, 4, 12, 30, 32) to H-2D. The remaining four (9, 16, If, 21) , because of the absence of the appropriate crossover, cannot yet be assigned to either locus, quite possibly when the necessary crossovers become available each will split into K and D components. The private H-2 specificities thus comprise two mutually exclusive series, one determined by H 2K, fine other by H 2D. They are generally strong, especially when tested by lymphocytotoxicity, though there may be some exceptions (2) .
Through the use of H-2 recombinants of congenic strain Fairs differing one from another only at H-2 (9) , and of hybrid recipients, it is possible to get donor-recipient pairs which differ by only a single private specificity, and to produce monospecific antisera to these specificities. Of necessity, antisera agains! the public specificities contain also an antibody against a private specificity, and sometimes to both H-2K and H-2D private speeificities. In some cases, it is impossible, with the haplotypes currently available, to selectively eliminate all the t?ublic specificities from strain combinations differing by only a single private specificity.
t)ne possible source of information concerning the H-2K and H-2D loci is studies o~" the alloantigenicity of their respective products. Several investigations have suggested that the two antigens differ in immunogenicity, the products of the H-2D locus appearing less immunogenic than those of the H-2K locus. Thus, antibodies against H-2K private specificities generally show a higher cytotoxic titer than antibodies against H-2D private specificities (2) , and lymphoma (10) and skin (11, 12) grafts differing from the recipient by private or combined private and public H-2K specificities are more rapidly rejected than those differing by H-2D specificities. The difference in the immune response to H-2K and H-2D antigens was also seen in an heterologous antiserum made to mouse lymphocytes (13) . Likewise, graft-vs.-host disease (11, 14, 15) and mixed lymphocyte reactions (16 18) are stronger in strain combinations with H-2K differences than in those with H-2D differences, and tolerance induction is easier (11) . Most of these tests have used only a few of the possible H-2K and H-2D combinations, and often public specificities have not been excluded. A partial reversal of the situation with respect to the relative strengths of H-2K and H-2D may be seen in the case of marrow grafts, where a postulated H]~-I (hybrid histocompatibility) locus at the D end of the H-2 complex is responsible for the rejection of parental bone marrow grafts made to irradiated F~ recipients (19) . Recent evidence, however, indicates that this affect may not be confined to the D end (20) .
In most of these experiments, multiple H 2 antigenic differences were present between donor and recipient. However, when a single H-2K antigenic difference was examined, specificity H-2.31, a number of factors affecting the intensity of the ensuing immune response became apparent. For instance, when a single H-2 antigenic difference was examined, enhancement could be produced for skin grafts (21) and a gene dose effect demonstrated (22) , neither being obtained when multiple t]-2 differences were present. We have therefore examined individual priwtte H-2K and 1]-2D antigenic specificifies to determine their role in immune responses. Using this model, it is apparent that the K and D regions of the H-2 complex give rise to antigens of consistently differing immunogenicity for cell-mediated and humoral responses, and that they differ in their response to passive immunological enhancement.
Materials and Methods
Mice.-All mice were from inbred strains maintained at the Jackson Laboratory, Bar
Harbor, Maine, except that mice of strain B10.S were kindly provided by Dr. J. Stimpfling but we have noted little differences using body skin grafts (21) . Strain C3H-II-2 ° was originally backcrossed to C3H/HeJSt, but the last two backcrosses were to C3H/HeDISn. We shall hereafter refer to the strains without the substrain symbols and for strains C57BL/10ScSn and C57BL/6J use the abbreviations B10 and B6, respectively.
Selection of Recipient-Donor Combinations.--Information concerning H-2 serotypes and H-2
recombinants, used in selecting reciplent-donor combinations, came from reviews by Shreffler (23) and Klein and Shreffler (3) . We also made use of an unpublished H-2 chart prepared by P. Demant, and of the classification of public and private specificities proposed by Snail et al. (2) . In so far as possible, recipient-donor combinations were chosen so that donor and recipient differed only by an H-2K private specificity or an II-2D private specificity. This entailed the use of donor and recipient H-2 haplotypes in congenic backgrounds to eliminate non-H-2 differences, and of a recombinant for either the donor or one parent of the recipient, or both, to restrict the differences to one end of H-2. It also usually entailed the use of hybrid recipients so as to restrict the response to the one chosen specificity, in a few cases public (presumably cross-reacting?) specificities could not be excluded; these are indicated in the tables. The essentially monospeeific private specificity differences thus achieved were: for H-2D, 2, 4, 30, 32; for H-2K, 15, 17, 23, 31, 33 The grafts were considered to be rejected when no viable epithelium remained on macroscopic examination of the graft. Second set grafts were placed on the left side of the recipient, 14 days after rejection of a first set skin graft on the right side. Male mice, 8 12-wk old, were used in all skin graft experiments, and there were 10-15 mice in each experimental group. The statistical analyses were done according the Litchfield (25) .
Production of Alloantlsera.--Reeipients for the production of alloantibodies were of mixed sexes and, with the exceptions noted below, at least 8-wk old; usually they were F1 hybrids. Immunizing injections were given intraperitoneally. The first two injections were thymocytes, one young donor per 25 recipients, given 40 days apart. Subsequent injections of cells pooled from thymus, spleen, and submaxillary gland, one donor per 10 recipients, given at weekly or two weekly intervals, The first bleeding was usually after the fourth injection. The rationale for this ~mmunization schedule has been given elsewhere (26) . Once a titer was estahlished, two bleedings on day 7 and 10 after the last injection were alternated with single injections. Bleedings were made from the tail. Antisera were stored in a freezer at --60°C. Antisera C-2, C 9, C-17, C-19, C-30, C-32, and C-33 were made available at the Jackson Laboratory under a National Institutes of Health contract, and were made available through the Transplantation Immunology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Mice used in the production of these antisera were 5-8-wk old at the time of the first injection rather than 8+ wk. On the other hand, the recipients in most cases received more than four injections before the first bleeding; the first bleedings of C-2 and C-32 were made after 13 injections. These antisera were made approximately 5 yr before their use in these tests. AS-377 was approximately 2-yr old when used. All other antisera were less than 1-yr old.
Antisera were also obtained by bleedings on days 10, 15, 20, 25, and 30 following first set skin grafts. Four mice were bled on each of these days and the sera tested individually by the "51Cr cytotoxic method.
Hemagglutlnating and Cytotoxic Tests.--Hemagglutination tests were performed by the PVP method of Stimpfling (27) with the addition of 0.1% bovine serum albumin (BSA). Details of the method as we use it are given in the Catalog of Mouse Alloantisera (28) .
Cytotoxic tests were performed using the ~lCr method to measure cell lysis (29) . Spleen cells were used as the target and were prepared free of red cells by flushing with Tris-NH4CI and incubating at 37°C for 5 mln. 50 #l of aaCr-labeled cells (at a concentration of 10G/ml) were mixed with 50 /~1 of antibody diluted in L15 medium (Microbiological Associates Inc., Bethesda, Md.) and 50/zl of rabbit complement added. Antiserum titers were calculated using semilog probit paper, the titer being defined as the antibody dilutions which caused the release of 50% of the maxinmm ~lCr available for release. The same pool of complement was used for all tests, which were performed in duplicate.
Enhancement Studies.--To produce passive enhancement of skin grafts, 0.1 ml of the alloantibody pool, reactive with the skin graft donor antigens, was given by the intraperitoneal route on days 0, 2, and 4 after the skin grafts. This regimen of antiserum administration had previously proved to be effective for the enhancement of skin grafts with an H-2K.31 difference (21) . Antibody production by mice bearing enhanced grafts was also studied by the atCr method described above. (Tables I and //) .--When D region and K region private specificities were compared, a difference in the time required for rejection was apparent. D region specificities produced slower rejections than did K region specificities. In recipient-donor combinations in male m~ce differing only by D region specificities (Table I) , median survival times (MST's) ranged from 13.8 4-1.1 days for H-2.4 to 18.6 4-1.6 days for H-2.32. For K region differences, the range was 9. 32 and H-2K specificity 31 were each tested in a number of recipient-donor combinations. Each showed considerable variation. For 32, the MST's ranged from 14.5 -4-1.3 to 18.6 4-1.6; for 31 they ranged from 9.8 4-1.0 to 14.5 4-1.0. In the discussion we shall consider some of the factors that may be responsible for this variability. 
RESULTS

First Set Skin Graft Rejections
> H-2.30 > H-2.2 = H-2.32. H-2D specificity
H-2 m H-2 a X H-2 b -- B10.AKM B10.A X LD C-30 1/32 1/1,280 NT NT H-2 m H-2 a X H-2 b H-2.13 AKR.M AKR X B10 AS-312 1/64 1/320 NT NT H-2 m H-2 k X H-2 b -- B10.BR B10 X A/J C-32 1/90 1/1,280 16.0 -4-1.2 7.8 4-1.2 H-2 k H-2 b X H 2 a -- C3H C3H.SW X AS
H_2 k H-2 m
* Groups of 15-20 male mice were used as recipients in each experiment. :~ The abbreviations used: C, mouse antisera from Catalogue of Mouse Alloantisera; AS, sera produced at The Jackson Laboratory; ASM, sera produced in the Department of Surgery, Massachusetts General Hospital by I. McK; NT, not tested; tr, trace.
§ The presence of H-2.47 in these sera is uncertain, as the recipient or a parent of the recipient has not been typed for this specificity.
In the combination for AS-541, B10.BR --~ C3H.SW X B10.A(2R), there is also an antigenic difference of TL. 1,2,3, as B10.BR is TL(+), and the recipients are TL(--). (37) Second Set Skin Graft Rejections (Tables I and//) .--The difference between D and K region antigenic specificities was also observed, but to a lesser extent, when second-set skin grafts were performed 10 days after the first grafts were rejected. When there was a D region difference, second set grafts showed an MST of 7.8-9.5 days. When there was a K region difference, the values were 6.8-8.2 days. While the H-2D rejections were slower than were those for H-2K, the shortening in graft survival time observed after priming with a first set skin graft was greater. Second set grafts performed in the presence of a D region antigenic difference were rejected up to 9 days earlier than a first set graft; when there was a K region difference grafts were rejected 2-4 days earlier.
Skin Graft Rejection in Hyperimmunized Mice.--The F1 hybrid female mice At the K region, cytotoxic antibody titers ranged from ~2 to ]/~,04s. Only 4 of 16 titers were ~/~2s or less, hence overlapping the D region range. As we shall point out in the Discussion, some of the variability was probably due to identifiable factors other than the properties of the antigen itself.
The hemagglutinating titers were difficult to interpret, as several H-2 specificities, notably 31, 32, and 33, do not usually lead to hemagglutinating activity.
However, several late bleeds after prolonged immunization contained antibody to H-2.33 (C-32 and AS-485). In addition, when H-2.17 was made in one combination (AS-545), no hemagglutinating antibody was detected. The difference between H-2D and H-ZK region specificities in the titers of cytotoxic antibody and in skin graft survival was not reflected in the titers for hemagglutinating antibodies. Antigenic specificities from both regions led to hemagglutinating antibody titers of 0 to 1/~,2s0.
Cytotoxic Antibody Formation after a First Set Skin Graft (Table///).--The
humoral response engendered by a skin graft was much more pronounced for H-2K than for H-bD differences. Cytotoxic antibodies were found consistently on day 10, the approximate time of rejection of skin grafts where K region specificities were present. The titers subsequently rose to a maximum of 1/~4 to 1/~56 on days 15 20, and then began to fall. By contrast, when there was an antigenic difference of a D region specificity, no cytotoxic antibody was detectable in six of nine combinations. In the other three, titers of }~ to 1/~ were present on days 10 or 15. No tests were run for hemagglutinating antibodies in these sera. Clearly, skin grafts performed when there is an H-bD specificity difference give rise to relatively poor humoral as well as poor cellular immune responses. * Cytotoxic antibody was measured by the 51Cr cytotoxic test. The titers are the approximate means obtained from testing, separately, the serum obtained from four mice.
Enhancement of Skin Grafts by the Passive Administration of AIloantibody to the Private H-2K and H-2D Specificities (Tables IV and V).--Althongh H-2K
Alloantibody reactive with donor antigens was given 0.1 ml on days 0, 2, and 4 after skin grafting to a group of 10-15 mice, the other group received no serum. Bleedings were performed on days 10, 15, 20, 25, and 30, after the graft § W, weak.
specificities appear to be more immunogenic for both cell-mediated and humoral immunities than are H-2D specificities, enhancement of skin grafts was far greater in the presence of H-2K than of H-2D region differences. Thus, graft prolongation of 2.4 to 6.7 days occurred with K region specificities, but of only 0.2 to 1.5 days with D region specificities. This is illustrated in Fig. 1 
(H-2D
region) showed a late rejection, but this was scarcely affected by passively administered anti-H-2.2. The degree of enhanceraent was similar for all K region specificities and was similar to that previously reported, for the K region specificity H-2.3I (21) . Although the earlier studies did not suggest that prolonged dosage affected the degree of enhancement attained (21) , it still seemed possible that the lack of enhancement for H-2D region antigens was due to the long interval between the last dose of antibody (4 days after the skin was grafted) and graft rejection, with a consequent disappearance of antibody. For example, for the D region specificity H-2.2, 14 days elapsed between the last dose of antibody and first set skin graft rejection, whereas for K region specificity H-2.31 the elapsed time was only 6 days. To exclude a possible insufficiency of antibody, 0.2 ml of C-32, anti-H-2.32, was given every second day until graft rejection occurred in the combination B10,BR into (B10 X A)F1. Enhancement was not increased, the grafts being rejected at the same time as with the standard three-dose regimen. Similarly, a dose of 0.5 ml on days 0, 2, and 4 had no effect on the inability to produce enhancement in this combination. sumed to be residual antibody, was still detectable on day 10, but absent on day 15. The studies of D region specificities could reveal no suppressive effect, there being little antibody formed even in untreated mice.
Antibody-Mediated Suppression of Alloantibody Formation (Table IH).--For
FIO. 1. The MST for skin grafts is shown for the two private antigens of the H-2 b haplotype: 1[-2.33 (H-2K) and H-22 (H-2D). In both cases, male (B10.D2 X A)FI recipients were used and received a B10.A(2R) graft (for H-2.2) or a B10.A(5R) graft (for H-2.33).
DISCUSSION
The H-2 system of the mouse is generally regarded as consisting of two alloantigen-determining loci, H-2K and H-2D. By appropriate choices of recipientdonor combinations, it has been possible to stud}-various manifestations of the immune response where recipient and donor differed by single, private H-2K or single, private H-2D specificities. The responses measured included the rejection tinles of first and second-set skin grafts, the lymphocytotoxic and hemagglutinating antibody responses engendered by multiple injections of donor tissue, the lymphocytotoxic response engendered by first-set skin grafts, and the degree to which immunological enhancement could be induced by the passive transfer of alloantibody. By all tests except the production of heinagglutinating antibody, where no K-D difference was observed, the K antigen appeared to be stronger than the D antigen. Thus the MST of grafts ranged from 9.3 to 14.5 days for K end differences, and from 13.8 to 18.6 for D end differences. On the other hand, enhancement was much greater for the stronger K end differences than for the weaker D end differences. For the former, it ranged from 2.4 to 6.7 day's, for the latter from 0.2 to 1.5 days.
Differences in the immunogenic strength of the H-2K and H-2D alloantigens similar to those reported here, have been observed also with heart (30) and kidney (31) transplants.
There was considerable consistency in both the H-2K and H-2D responses. Nevertheless, there is reason to believe that there were in both sets of tests a number of identifiable variables which, if they could have been eliminated, would have made the results at each locus more uniform and the differences between the loci even more striking. Some of these variables are as follows.
The Tla locus is closely linked with H-2, and some 11-2 congenic stocks consequently differ at Tla as well as H-2. While Tla is primarily demonstrable through the cytotoxicity of thymic lymphocytes, it has recently been shown that it causes, or is associated with, a weak histocompatibility (32, 33) . In our D end 11-2.32 combination, B10.BR into B10.A(2R) X C3H.SW (Table I) , the donor was Tla-1, 2, 3 and the recipient Tla-negative. The MST for this combination, 14.5 ~ 1.3 days, was the second lowest. In our two 11-2.9 combinations (Table II) , the donor was probably TIa-1, 2, 3, the recipients Tla-2/Tla-negative. The effect of Tla on histocompatibility in this particular combination has not been determined. The MST's were within the normal range.
There are a number of H-2 private specificities which include two or three public specificities. These can be interpreted as the manifestation of cross-reactions. Thus anti-H-2.25 may be an antibody reacting with both H-2.1g and 1t-2.23. If there are indeed such cross-reactions, one might expect that strain combinations in which the antigens of recipient and donor are cross-reacting, and hence antigenically related, will give relatively weak immune responses. The two tt-2.23 combinations (Table lI) are a possible example, since H-2.1g was present in the recipient. The first of the two combinations, B10.A into B10.RIII(71NS) N PL/J, moreover, probably blocks a second cross-reaction. Strain PL/J (H-2 ~) has been shown to react with anti-23 antisera (34, no symbol has been assigned). Not surprisingly, this combination showed both a slow rejection for a K end difference (MST 11.5 ± 1.1) and a particularly weak cytotoxic titer (1/70). The second combination, sharing only 11-2.25, gave a somewhat weak antibody (titer 1/256) but a normal MST (10.2 4-0.8). It is also noteworthy that H-2.4, which appeared to be the strongest of all D end specificities, was studied in a combination which failed to exclude three or four potential cross-reactions, though this may merely mean that one of the determinants of antigenic "strength" is the capacity to trigger a diversity of antigen-reactive cell clones. In one 11-2.18 combination, B10.RIII (71NS) into B10 X A/J, in which cross-reacting antibody 11-2.25 was blocked, the immune responses appeared particularly strong. But H-2.1S is exceptional in that it is presumably the sum of both K and D private specificities.
It has been reported that DBA/1 and DBA/1 hybrids mount a particularly weak resistance to skin and tumor allografts (35, 46) . In five cases involving specificities H-2.17, H-2.1g, and H-2.31 (Table II) , DBA/1 or a DBA/1 congenic line was one parent of the recipient. In four of these five cases the other parent was B10 or a B10 congenic. These four cases showed relatively slow graft rejection for K end combinations (MST's of 12.5, 11.2, 12.2, and 11.4) and relatively poor antibody production (cytotoxic titers of 1/512, 1/300, 1/32, 1/32). In the fifth combination, DBA/1 into D1.C X AKR.M, graft rejection and cytotoxic antibody production were slightly stronger than average.
In four of the donor-recipient combinations in Tables I and II , the recipients were either nonhybrids or a hybrid between congenie partners. With the one exception B 10.BR into B10.AKM, where graft rejection was rapid, these combinations showed slow rejections and low antibody titers. This could mean that absence of hybrid vigor weakens the immune response. Alternatively, or in addition, the unhybridized B10 genetic background may be unfavorable to some H-2 immune responses.
As noted under Methods, the seven "C" antisera were produced with a somewhat different immunization schedule than the "AS" or "ASM" antisera, and were much older when used. The cytotoxic titers were generally somewhat low.
H-2 is the prototype of a "strong" histocompatibility "locus" (37) . Now that it is known to consist of linked loci, which can be studied separately, the question of its strength is open to reexamination. H-2K still appears as a uniquely strong locus, in terms of skin graft rejections, almost as strong as the undivided H-2 complex. It is very clear from this study that H-2D is somewhat weaker. But compared with non-H-2 loci, for which the shortest MST's are of the order of 20-25 days (38) , it still appears as relatively strong.
H-2K
and H-2D are unique among histocompatibility loci in the ease with which they are demonstrated by serological as well as transplantation techniques. They are closely linked and perhaps the product of reduplication of a single, ancestral locus (34, 39) . Antisera made against the antigen of one sometimes cross-react with the antigen of the other (3, 40, Snell and Cherry, unpublished data). The H-2K and H-2D antigens show considerable chemical similarity (41) . With all these indications of similarity, why is one locus associated with stronger immune responses than the other?
It is possible that the difference is in part an artifact, the product of unfavorable immune response genes in some or all of the combinations in which H-2D has been studied. Lilly et al. (42) showed that B10 and some of its congenic partner strains are poor responders to D end specificity It-2.2, and Stimpfling and Durham (43) demonstrated a role of the H-2 region itself on the response to H-2.2. This may apply also to other D end specificities (44, McKenzie, Cherry, and Snell, unpublished data). As a case in point, AS-543, B10.AKM anti-B10.BR, did not contain the anticipated anti-32. H-2D has usually been studied in combinations in which B10 and its congenics are present. But when the best combinations which we have encountered for the production of anti-H-2D are compared with the best combinations for the production of H-2K, the difference still remains substantial.
Despite the demonstrable chemical similarities of H-2K and H-2D, it is possible that undetected chemical differences account for the differences in antigenic strength. But this is no direct evidence in support of such a possibility.
The I-I-2 complex plays a major role in the mixed lymphocyte reactions (45, 46) . Lymphocytes differing at H-2 regularly show stimulation in mixed cultures, whereas, with a few major exceptions, non-//-2 combinations do not stimulate or stimulate weakly. Most of the mixed lymphocyte reactivity of the H-2 complex resides in the K end, the D end playing only a minor role (4, 16-18, 47, 48). Originally, it was assumed that the 11-2 loci themselves were the responsible agents, but recent evidence, based on the use of certain critical recombinants, indicates that the effect maybe due primarily to other components of the complex (4, 47) . A major part of the activity seems to be due to Ir-1, or some locus not now separable from it, but there is a weaker center of activity near to but independent of H-2D.
The critical recombinant haplotypes with respect to K end mixed lymphocyte reactivity are H_2y-~J and H-2 y-s~. These are identical with respect to H-2K and H-2D but, as a result of recombinations at the extreme left and right ends, respectively, of the complex, differ at It-1 and SsSlp. H-2 ~-Kzj arose from a rare crossover between H-2K and It-l, thus providing a source of information as to the effect of these loci separately. These particular recombinant haplotypes were not used in our tests.
Another example of unexplained reactivity associated with the K end of H-2 is provided by the H-2 mutant, H-2 ~a (49) . Skin grafts exchanged between the original and the mutant haplotypes are strongly rejected, but numerous tests failed to reveal any serological difference. F1 tests with appropriate recombinant haplotypes localized the effect at the K end. Whether the change is at H-2K itself, or at some closely linked, heretofore undetected histocompatibility locus is unknown.
There are thus, at the K end of the It-2 region, known or postulated loci, other than H-2K itself, which can engender immune or at least blastogenic responses. This makes it tempting to assume that part of the unusual strength of H-2K as compared to H-2D is due to these companion loci. From what is known of these loci, it can plausibly be supposed that they contribute part of the potential for rapid graft rejection associated with the K end. However, since it is a primary characteristic of these loci that they are not demonstrable serologically, they donot serve to explain the strong serological responses associated with the K end.
Perhaps the most surprising property of the K end revealed in these studies is the relative success of the enhancement of graft survival by passively transferred antibody. Graft prolongation was generally less than 1 day in the D end tests, generally more than 4 days in the K end tests.
The poor response of H-2D seems not to be due to some intrinsic resistance of the H-2D alloantigenic specificities to immunosuppression. Demant et al. (50) have shown that rabbit antimouse lymphocyte serum more than doubles the survival of skin grafts with an H-2D difference. Grafts with an H-2K difference responded less effectively. Also, host irradiation can substantially prolong the survival of grafts across the H-2D barrier (51) .
If the K end loci other than H-2K do not determine antibody-inducing antigens, they cannot provide an explanation of the efficiency of K end enhancement. Another possibility is that K end antibodies enhanced better simply because they were stronger. However, there was little correlation between antibody titer and enhancement. Thus K end antibody AS-563, anti-H-2.31, with a cytotoxic titer of 1/~2 , produced a prolongation of 4.2 days, whereas D end antibody AS-377, anti-H-2.4, with a cytotoxic titer of }~2s, produced a prolongation of only 0.7 days. Also we have previously demonstrated enhancement with an anti-H-2.31 (K end) with a dose as low as 0.1 /~1 (52). It is of course possible that cytotoxic titers are a poor measure of the concentration of enhancing antibody, but there is no direct evidence for this. At the moment there seems to be no good explanation of the relative enhanceability of grafts with an H-2K difference.
SUMMARY
The imnmnogenicity of single, private H-2 specificities has been tested. In most cases, the specificity was known to be confined either to H-2K or to H-2D. This was accomplished by the appropriate choice, as donor and recipient, or parent of the F1 hybrid recipient, of congenic strains differing at [t-2 only, and of recombinant haplotypes in donor and/or recipient.
By nearly all tests, the H-2K antigen appeared to be a stronger immunogen than the II-2D antigen. Skin grafts with an H-2K difference showed median survival times (MST) of 9.3-14.5 days; for H-2D the values were 13.8-18.6. The difference was also present, though narrowed, for second-set grafts. II-2K grafts regularly engendered a demonstrable cytotoxic antibody response; with H-2D differences the response was absent or very weak. K end cytotoxic titers after nmltiple immunizations with lymphoid tissues ranged from 1/t 2 to 1/6,048 , D end fiters from 0 to 1/~28. Hemagglutinafion titers showed no clear difference.
The results of passive enhancement of skin grafts with H-2 alloantibody produced in donor recipient combinations, identical to those used for the skin grafts showed a different pattern. H-2K, despite its greater immunogenic strength was more easily enhanced than H-2D. Prolongation of MST's for H-2K was 2.4-6.7 days, for H-2D grafts, 0.2-1.5 days.
